Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Fudan University
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
stage IB-IIIA, operable non-small cell lung cancer, confirmed in tissue.
Able and willing to give written informed consent and has signed the informed consent form (ICF), prior to performance of any trial activities.
Eligible male and female subjects aged 18-75 years.
Lung function capacity capable of tolerating the proposed lung surgery.
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1.
Available tissue of primary lung tumor.
You may not be if
Presence of locally advanced, inoperable or metastatic disease.
Subjects with EGFR mutation or ALK、ROS1 gene rearrangement.
Active, known or suspected autoimmune disease.
Prior treatment with any drug that targets T cell co-stimulations pathways (such as checkpoint inhibitors).
Clareo Health | Evaluate the Efficacy and Safety of Serplulimab Plus Chemotherapy in Neoadjuvant and Adjuvant Treatment of Resectable NSCLC (ECTOP-1013)
